Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567205 | 1.00 | OPRM1 (0.59) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4464330 | 0.98 | OPRM1 (0.58) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL6831189 | 0.98 | OPRM1 (0.61) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL1660644 | 0.95 | OPRM1 (0.61) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL31557718 | 0.91 | OPRM1 (0.64) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL737743 | 0.83 | OPRM1 (0.57) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL21873952 | 0.83 | OPRM1 (0.57) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL613629 | 0.82 | ALDH1A1 (0.56) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL10389866 | 0.82 | OPRM1 (0.67) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL6663444 | 0.82 | ALDH1A1 (0.60) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017066742-A1 | BACE-2 INHIBITORY COMPOUNDS AND RELATED METHODS OF USE | JORTAN PHARMACEUTICALS INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| CN-101674728-A | Reducing side effects of tramadol | DMI BIOSCIENCES INC | 2010-03-17 | — | — | CN | disclosed |
| CN-101657101-A | Treatment of comorbid premature ejaculation and erectile dysfunction | DMI BIOSCIENCES INC US | 2010-02-24 | — | — | CN | disclosed |
| CN-101508691-A | Sulphaminic acid benzothiophene ester derivative used as steroid sulfatase restrainer | THERAMEX SAM LAB (MC) | 2009-08-19 | — | — | CN | disclosed |
| CN-100491370-C | Benzothiophenesulfonate derivatives as steroid sulfatase inhibitors | THERAMEX (MC) | 2009-05-27 | — | — | CN | disclosed |
| WO-2009018169-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008151156-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| CN-101175482-A | Abuse-proofed dosage form | GRUENENTHAL GMBH (DE) | 2008-05-07 | — | — | CN | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| CN-1771243-A | Benzothiophenesulfonate derivatives as steroid sulfatase inhibitors | THERAMEX (MC) | 2006-05-10 | — | — | CN | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| US-6780891-B2 | MODULATE OPIATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | SEPRACOR INC. | 2004-08-24 | — | — | US | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| US-20030171440-A1 | Tramadol analogs and uses thereof | SEPRACOR INC. | 2003-09-11 | — | — | US | disclosed |
| WO-2003048113-A1 | TRAMADOL ANALOGS AND USES THEREOF | SEPRACOR INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-5384078-A | Reaction of dienes with epoxides and carbon dioxide to form lactones for reaction with calcium | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1995-01-24 | — | — | US | disclosed |
| US-5211889-A | Organocalcium cuprate complexes formed by reduction | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993003044-A1 | REACTIVE FORM OF CALCIUM AND REAGENTS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171440-A1 | Tramadol analogs and uses thereof | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | OPRM1 190/4885OPRD1 431/4885OPRK1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.